

Pharmacological Innovations in Steroid-Sparing Agents: Emerging Biologic Therapies and their Ethical Implications

Mpora Kakwanzi Evelyn

Department of Pharmacognosy Kampala International University Uganda
Email: evelyne.mpora@studwc.kiu.ac.ug

ABSTRACT

The chronic use of corticosteroids, long a cornerstone in the treatment of autoimmune and inflammatory disorders, is increasingly being reevaluated due to their well-documented long-term adverse effects. Recent advances in pharmacology have introduced biologic and targeted synthetic therapies as effective steroid-sparing agents, offering enhanced disease control with fewer systemic side effects. This review explores the mechanisms, clinical efficacy, and safety profiles of these emerging therapies, including monoclonal antibodies and Janus kinase inhibitors, in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. While these biologics mark a paradigm shift in immunomodulatory treatment, their high cost and limited accessibility particularly in low- and middle-income countries raise pressing ethical concerns. Issues such as equitable access, informed consent, financial sustainability, and the influence of pharmaceutical marketing are examined through an ethical lens. The review also evaluates policy and regulatory frameworks, highlighting the potential of biosimilars, personalized medicine, and digital health tools to improve access and optimize care. By integrating clinical, pharmacological, and ethical perspectives, this study proposes strategic recommendations to support equitable, evidence-based, and sustainable implementation of steroid-sparing therapies in global healthcare systems.

Keywords: Steroid-sparing agents, Biologic therapies, Autoimmune diseases, Corticosteroids

INTRODUCTION

The treatment of autoimmune and inflammatory disorders has evolved considerably over the past few decades. For many years, corticosteroids have served as a mainstay therapy due to their potent anti-inflammatory and immunosuppressive properties [1]. They have been instrumental in managing conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS), among others [2]. Their efficacy in rapidly controlling inflammation and reducing disease activity is well documented, making them a go-to intervention for acute disease flares and severe cases.

However, the chronic use of corticosteroids is not without consequences. Prolonged administration is associated with a multitude of adverse effects, ranging from metabolic complications like diabetes mellitus and dyslipidemia, to musculoskeletal issues such as osteoporosis and avascular necrosis [3]. Furthermore, patients on long-term steroid therapy are at increased risk of infections, psychiatric disturbances, hypertension, and Cushingoid features. These side effects not only compromise the patient's quality of life but also impose a considerable burden on healthcare systems due to increased morbidity and hospital admissions [4].

The emergence of biologic and targeted synthetic therapies represents a significant pharmacological innovation in the field of immunology and inflammatory disease management [5]. These steroid-sparing agents work by selectively targeting specific components of the immune system, such as cytokines (e.g., tumor necrosis factor-alpha, interleukins) or immune cell receptors, thereby offering a more tailored approach to immunomodulation. Examples include monoclonal antibodies like infliximab and adalimumab, Janus kinase (JAK) inhibitors like tofacitinib, and

interleukin-17 inhibitors like secukinumab. These agents have been increasingly integrated into clinical guidelines and are often preferred for patients who are steroid-dependent or at high risk of steroid-related complications [6]. The clinical advantages of these therapies are clear—they reduce the need for systemic steroids, minimize side effects, and often result in better disease control and patient adherence. However, their rising use has introduced new ethical and systemic challenges [7]. These include issues related to cost-effectiveness, insurance coverage, disparities in access, informed consent, and the long-term safety data of these relatively newer interventions. In low- and middle-income countries, access to biologics remains limited, exacerbating health inequities. Furthermore, patients and clinicians are sometimes faced with dilemmas about whether to continue inexpensive but riskier steroid treatments versus adopting safer but costly biologic therapies.

This shift from broad-spectrum immunosuppressive therapy to precision-based biologic interventions marks a significant turning point in patient care, demanding a reevaluation of pharmacoeconomic priorities, ethical obligations, and clinical decision-making frameworks [8].

Despite their therapeutic effectiveness, the long-term use of corticosteroids is fraught with serious health risks and diminished patient quality of life. While the introduction of biologic therapies and other steroid-sparing agents has provided an alternative means of disease control, their high cost and uneven global availability present significant barriers [9]. Moreover, ethical concerns about equitable access, patient autonomy in therapeutic choices, and the sustainability of healthcare systems in affording these advanced treatments have not been adequately addressed in many clinical and policy discussions.

A pressing issue is the lack of standardized guidelines to navigate the ethical considerations arising from the use of these agents, especially in vulnerable populations. Many healthcare providers struggle with the balance between offering optimal care and adhering to budgetary or institutional constraints [10]. In parallel, patients often make treatment decisions without fully understanding the long-term implications, risks, or alternative therapies available. This knowledge gap can result in suboptimal outcomes and decreased trust in the healthcare system.

This study aims to explore the pharmacological mechanisms and clinical efficacy of emerging biologic and steroid-sparing agents used in treating autoimmune and inflammatory disorders. It will analyze the short- and long-term safety profiles of these agents compared to traditional corticosteroid therapy, identify and evaluate the ethical implications associated with the prescription, access, and use of biologic therapies, particularly in resource-limited settings, and examine socio-economic factors influencing patient access and adherence to biologic treatments. The study will propose ethically grounded policy recommendations and clinical strategies for equitable and sustainable use of steroid-sparing agents. The study holds significant significance in both the medical and ethical domains of healthcare, as understanding the broader implications of biologic therapies is essential for informed clinical practice and policymaking. It will provide updated insights into the efficacy and safety of newer steroid-sparing agents, aiding healthcare professionals in making evidence-based treatment decisions and identifying potential adverse events and long-term risks. From an ethical and policy standpoint, the study seeks to highlight the disparities in access to advanced therapies and the moral obligations of healthcare systems to address these gaps. It will contribute to the ongoing dialogue on equitable healthcare delivery and may inform future guidelines for the ethical prescription of costly treatments.

Overview of Biologic and Targeted Therapies

Biologic therapies represent a class of advanced treatments derived from living organisms, typically through recombinant DNA technology [11]. These agents are engineered to target specific molecular components involved in immune system regulation, distinguishing them from conventional therapies such as corticosteroids, which have broad and non-selective immunosuppressive effects. Biologics act by inhibiting cytokines, blocking cellular receptors, or depleting specific immune cell populations responsible for pathological inflammation. For instance, anti-tumor necrosis factor (anti-TNF) agents like infliximab and adalimumab neutralize TNF- α , a pro-inflammatory cytokine implicated in many autoimmune diseases. Interleukin inhibitors such as tocilizumab (IL-6), secukinumab (IL-17), and ustekinumab (IL-12/23) further illustrate the precision of these treatments. B-cell depleting agents like rituximab target CD20 on B-lymphocytes, while Janus kinase (JAK) inhibitors such as tofacitinib and baricitinib, although small molecules, function analogously by disrupting intracellular signaling pathways central to immune activation [12].

The clinical utility of biologic and targeted therapies has revolutionized the management of chronic inflammatory and autoimmune disorders. They are now standard treatments for conditions including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), asthma, and atopic dermatitis. These agents offer enhanced disease control, reduced flare frequency, and a decreased reliance on long-term corticosteroid therapy, ultimately improving patient outcomes and quality of life.

Pharmacological Advancements and Outcomes

Pharmacological advancements in biologic therapies have significantly transformed the treatment landscape of autoimmune and inflammatory diseases. Clinical trials and observational studies have consistently demonstrated that these agents offer superior efficacy in inducing and maintaining disease remission compared to traditional corticosteroids [13]. They are particularly effective in managing conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where conventional treatments may fail to achieve sustained control. Importantly, biologics present a more favorable safety profile, particularly in long-term use, by reducing the risks associated with chronic corticosteroid therapy such as osteoporosis, hypertension, hyperglycemia, and immunosuppression. Furthermore, innovations in drug delivery systems—such as subcutaneous self-injections and long-acting injectables—have improved treatment adherence, reduced healthcare visits, and enhanced patient convenience and outcomes.

A major advancement in this field is the integration of personalized medicine through the use of predictive biomarkers. These biomarkers, including genetic, proteomic, and immunologic indicators, help clinicians identify patients who are most likely to respond to specific biologic agents [14]. This precision-based approach minimizes trial-and-error prescribing, reduces the risk of adverse effects, and optimizes resource utilization. By tailoring therapies to individual patient profiles, personalized medicine enhances both the clinical efficacy and safety of biologic treatments.

Ethical Implications

The introduction of biologic therapies, while revolutionary in managing autoimmune and inflammatory disorders, raises significant ethical concerns, particularly in relation to access, prescribing practices, and resource allocation [15]. Equitable access is a foremost challenge, as biologics are often prohibitively expensive compared to traditional corticosteroids. This cost disparity risks exacerbating health inequities, especially in low- and middle-income countries (LMICs), where limited healthcare budgets and weak insurance infrastructures may preclude access for the majority. Disparities also arise within wealthier nations due to inconsistent insurance coverage and regional differences in reimbursement policies. To promote global health equity, there is a pressing need for strategies such as the accelerated approval of biosimilars, implementation of tiered pricing, and public-private partnerships to reduce costs.

From the perspective of ethical prescribing, clinicians must navigate the complex balance between offering the most effective treatment and considering its financial burden on patients or healthcare systems [16]. Transparent communication during the informed consent process is crucial, with patients needing to understand not just therapeutic benefits but also potential long-term costs and risks. Additionally, physicians must guard against conflicts of interest, especially where pharmaceutical incentives may unduly influence clinical decisions.

Finally, allocation of resources in publicly funded systems poses ethical dilemmas. Decision-makers must weigh the high costs of biologics against population-level needs, applying ethical frameworks—such as utilitarianism, which prioritizes overall benefit, and egalitarianism, which emphasizes equal access—to determine just distribution of scarce healthcare resources [17]. Striking a fair balance requires inclusive policy-making that reflects societal values and healthcare priorities.

Regulatory and Policy Considerations

As the use of biologic therapies expands in the treatment of autoimmune and inflammatory diseases, regulatory and policy frameworks play a pivotal role in shaping their ethical and equitable deployment. One of the most significant developments in this arena is the emergence of biosimilars—biologic products that are highly similar to already approved reference biologics. The introduction of biosimilars presents a critical opportunity to reduce treatment costs and broaden access, particularly in low- and middle-income countries. However, for biosimilars to gain widespread acceptance, regulatory agencies must strike a delicate balance between maintaining stringent approval standards and fostering a competitive market environment that incentivizes innovation while safeguarding patient safety and therapeutic efficacy [18].

In addition to regulatory oversight, international guidelines and ethical standards have been developed by professional medical associations to guide clinicians in the responsible use of biologics. These guidelines emphasize the primacy of clinical need over commercial interests, advocate for transparent communication that supports patient autonomy, and encourage healthcare providers and institutions to engage in policy reform aimed at improving access. Ethical prescribing practices must therefore be embedded within a broader healthcare policy framework that supports equitable access, patient-centered care, and sustainable therapeutic innovation across diverse global health systems.

Future Directions

The future of steroid-sparing therapies lies in a multifaceted approach that embraces innovation, technology, and global cooperation. One of the most promising avenues is the development and approval of biosimilars—biologic

medical products that are highly similar to already approved biologic therapies. As biosimilars become more widely available, they have the potential to significantly reduce treatment costs while maintaining therapeutic efficacy, thus expanding access to life-changing therapies for patients in low- and middle-income countries [19].

Moreover, the integration of digital health tools, including artificial intelligence (AI) and machine learning, offers a powerful means to personalize treatment strategies. These technologies can analyze vast datasets to predict patient responses to specific biologic agents, enabling clinicians to select the most effective and safest therapy with greater precision. This would not only optimize clinical outcomes but also reduce healthcare waste associated with ineffective treatments.

Equally important is global collaboration. Coordinated efforts among governments, non-governmental organizations (NGOs), and pharmaceutical companies will be essential to address disparities in biologic access [20]. These partnerships can facilitate equitable distribution, support capacity building in healthcare systems, and promote policies that prioritize both innovation and inclusivity. Collectively, these future directions aim to foster a more ethical, efficient, and globally accessible framework for steroid-sparing therapies.

CONCLUSION

The evolution from corticosteroids to biologic and targeted therapies marks a pivotal advancement in the management of autoimmune and inflammatory diseases. These steroid-sparing agents offer enhanced efficacy and improved safety profiles, reducing the burden of long-term corticosteroid-associated complications. However, their high cost, limited availability in resource-constrained settings, and the complexities of equitable access introduce pressing ethical concerns. Addressing disparities in access, ensuring informed patient choice, and aligning prescribing practices with ethical principles are critical challenges facing healthcare systems globally. The advent of biosimilars offers a promising path toward broader access and reduced treatment costs, but must be supported by robust regulatory frameworks and international cooperation. Future strategies should prioritize integrating digital health tools, advancing personalized medicine, and promoting ethical policy development that balances innovation with equity. By bridging clinical efficacy with ethical responsibility, stakeholders can ensure that pharmacological innovations truly translate into sustainable and inclusive healthcare solutions for all patients, regardless of socioeconomic status or geographic location.

REFERENCES

1. Alum, E. U., Ibiyam, U. A. and Ugwu, O. P. C. A Comprehensive Review of Treatment Approaches and Perspectives for Management of Rheumatoid Arthritis. *INOSR Scientific Research*. 2023; 10(1):12-17. <https://doi.org/10.59298/INOSRSR/2023/2.2.13322>
2. Cheng, X., Meng, X., Chen, R., Song, Z., Li, S., Wei, S., et al.: The molecular subtypes of autoimmune diseases. *Computational and Structural Biotechnology Journal*. 23, 1348–1363 (2024). <https://doi.org/10.1016/j.csbj.2024.03.026>
3. Alum, E. U. and Ugwu, O. P. C. Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. *INOSR Scientific Research*. 2023; 10(1):18-26. <https://doi.org/10.59298/INOSRSR/2023/3.2.47322>
4. Nasereddin, L., Alnajjar, O., Bashar, H., Abuarab, S.F., Al-Adwan, R., Chellappan, D.K., Barakat, M.: Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications. *Diseases*. 12, 300 (2024). <https://doi.org/10.3390/diseases12120300>
5. Armin R., Gavin T, Madeline S, Andrea L H, Jessica A W, Jessica K, et al (2021). Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. *British journal of haematology*, 192, 3. [Dio 10.1111/bjh.17238](https://doi.org/10.1111/bjh.17238)
6. Lortholary, O., Fernandez-Ruiz, M., Baddley, J.W., Manuel, O., Mariette, X., Winthrop, K.L.: Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. *Annals of the Rheumatic Diseases*. 79, 1532–1543 (2020). <https://doi.org/10.1136/annrheumdis-2020-217092>
7. Margaret L M, Shernan G H, Armin R, Todd E D, Claudio G B, John E W, et al (2018). Validation of minnesota acute GVHD risk score and identification of new factors associated with initial response to steroids: not all GVHD is created equal. *Blood*, 132, 67, <https://doi.org/10.1182/blood-2018-99-113085>
8. Bolous, N.S., Chen, Y., Wang, H., Davidoff, A.M., Devidas, M., Jacobs, T.W., et al.: The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. *Blood*. 138, 1677–1690 (2021). <https://doi.org/10.1182/blood.2021010864>
9. Celalettin U, Jacqueline B, Debra A M, Eris T, Marisa M, Armin R, et al (2020). Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. *Bone marrow transplantation*, 55, (4), 833-835.

10. Abdulrazeq, F., März, J., Biller-Andorno, N., Gastmans, C.: Healthcare providers' advocacy approaches and ethical challenges in delivering healthcare to undocumented migrants: a scoping review. *Medicine, Health Care and Philosophy*. 27, 579–606 (2024). <https://doi.org/10.1007/s11019-024-10225-8>
11. Iskit, A.B.: Key concepts in biosimilar medicines: What physicians must know. *North Clin Istanb*. 9, 86–91 (2022). <https://doi.org/10.14744/nci.2021.84669>
12. Shernan G H, Ashraf S, Armin R, Brian C B, Margaret L M, Celalettin U, et al (2019). RNA Sequencing of Intestinal Biopsies Expands the T Cell-Centric Paradigm of Steroid-Refractory Acute Graft-Versus-Host Disease. *Biology of Blood and Marrow Transplantation*, 25, (3), S295.
13. Drosos, A.A., Pelechas, E., Kaltsonoudis, E., Markatseli, T.E., Voulgari, P.V.: Biologic Therapies and Autoimmune Phenomena. *Mediterr J Rheumatol*. 32, 96–103 (2021). <https://doi.org/10.31138/mjr.32.2.96>
14. Sharma, H., Pathak, R., Halagali, P., Tippavajhala, V.K., Rathnanand, M.: Chapter 11 - Predictive biomarkers: guiding personalized cancer therapies. In: Prabhakar, P.K. (ed.) *The Potential of Cancer Biomarkers*. pp. 239–262. Elsevier (2025)
15. Hamid A.A, Kaushal T., Ashraf R., Singh A, Gupta A. C, Prakash O. M, et al (2017). (22β, 25R)-3β-Hydroxy-spirost-5-en-7-iminoxy-heptanoic acid exhibits anti-prostate cancer activity through caspase pathway. *Steroids* 119, 43-52. <https://doi.org/10.1016/j.steroids.2017.01.001>
16. Varkey, B.: Principles of Clinical Ethics and Their Application to Practice. *Med Princ Pract*. 30, 17–28 (2021). <https://doi.org/10.1159/000509119>
17. O'Sullivan, L., Aldasoro, E., O'Brien, Á., Nolan, M., McGovern, C., Carroll, Á.: Ethical values and principles to guide the fair allocation of resources in response to a pandemic: a rapid systematic review. *BMC Medical Ethics*. 23, 70 (2022). <https://doi.org/10.1186/s12910-022-00806-8>
18. Jarab, A.S., Abu Heshmeh, S.R., Al Meslamani, A.Z.: Bridging the gap: The future of biosimilars regulations. *Hum Vaccin Immunother*. 20, 2362450. <https://doi.org/10.1080/21645515.2024.2362450>
19. Ntais, C., Kontodimopoulos, N., Fanourgiakis, J., Talias, M.A.: Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis? *F1000Res*. 13, 1128 (2025). <https://doi.org/10.12688/f1000research.156983.2>
20. Ngoma, C., Phiri, W.K.B., Chidzaye, R., Lungu, S., Matatiyo, A., Shantel Mwase, M., Nyimba, W.: Enhancing public health through multi-stakeholder collaboration in Africa. *Ann Med Surg (Lond)*. 86, 5672–5675 (2024). <https://doi.org/10.1097/MS9.0000000000002532>

CITE AS: Mpora Kakwanzi Evelyn (2025). Pharmacological Innovations in Steroid-Sparing Agents: Emerging Biologic Therapies and their Ethical Implications. EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES, 6(3):90-94